Vasodilator Therapy

Introduction to Vasodilators

• The European Society of Cardiology notes that vasodilators have various adverse effects, including hypotension, reflex tachycardia, headache, dizziness, flushing, and fluid retention, with specific side effects varying based on the class of vasodilator used 1, 2

Hemodynamic Effects

• Hypotension can cause dizziness, lightheadedness, syncope, reduced organ perfusion, and collapse in severe cases, according to the European Heart Association 1
• Reflex tachycardia occurs as a compensatory mechanism to maintain cardiac output when peripheral resistance decreases, more common with direct arterial vasodilators, and may worsen myocardial ischemia in susceptible patients, as stated by the European Society of Cardiology 2

Fluid Balance and Electrolytes

• Fluid retention, particularly with hydralazine, often requires concomitant diuretic therapy, as recommended by the American Heart Association 3
• The following dosing guidelines are recommended:

4, 5

Tolerance and Rebound Effects

• Tachyphylaxis can develop after 24-48 hours of continuous use, according to the European Journal of Heart Failure 6

Specific Adverse Effects

• Peripheral edema is particularly common with dihydropyridines, as noted by the American Academy of Pediatrics 7
• Constipation is more common with verapamil, according to the American College of Cardiology 8
• Gingival hyperplasia can occur with long-term use, as stated by the American Academy of Pediatrics 7
• Drug-induced lupus-like syndrome risk increases with higher doses (>100 mg daily), as warned by the American Heart Association 3
• Common adverse effects of hydralazine include headache, dizziness, flushing, gastrointestinal complaints, reflex tachycardia, sodium and water retention, and vomiting, and it is associated with drug-induced lupus-like syndrome at higher doses 9, 5, 10

Contraindications and Precautions

• Vasodilators should be used with extreme caution in patients with severe aortic stenosis, as advised by the European Society of Cardiology 1
• Vasodilators may worsen obstruction in patients with hypertrophic cardiomyopathy with outflow obstruction, according to the American College of Cardiology 8
• In acute heart failure, vasodilators should be avoided in patients with systolic blood pressure <90 mmHg, as recommended by the European Society of Cardiology and the European Journal of Heart Failure 1, 6
• The American College of Obstetricians and Gynecologists prefers labetalol in many cases of severe preeclampsia, with hydralazine as an alternative, and recommends that the cumulative dose of labetalol should not exceed 800 mg/24h to prevent fetal bradycardia 11, 12

Ineffectiveness and Toxicity

• Oral vasodilator prostaglandins (beraprost, iloprost) are not effective for improving walking distance in patients with intermittent claudication, as stated by the American Heart Association 13
• Cyanide toxicity can occur with prolonged use, especially in patients with renal dysfunction, as warned by the European Society of Cardiology 2
• The American Heart Association recommends hydralazine combined with isosorbide dinitrate as add-on therapy to standard regimens, which may include beta-blockers like labetalol, with a 43% relative risk reduction in mortality in African American patients with heart failure with reduced ejection fraction (HFrEF) 10, 14

Dosing and Administration

• The FDA-approved oral dosing range for hydralazine is 100-200 mg daily in 2-3 divided doses, with initial doses starting at 10-25 mg three times daily and gradual increases by 10 mg increments 4, 5
• The initial dose of hydralazine for heart failure is 37.5mg with 20mg isosorbide dinitrate three times daily, with a target dose of 75mg hydralazine with 40mg isosorbide dinitrate three times daily, and dose up-titration should be considered after 2-4 weeks if tolerated 15

Monitoring and Precautions

• Regular blood pressure monitoring is recommended after each dose increase, as well as monitoring for symptomatic hypotension, reflex tachycardia, and bradycardia, according to the European Society of Cardiology 11
• Blood pressure should be monitored after each dose increase, with patients monitored for symptomatic hypotension, such as dizziness and lightheadedness, and titration should occur gradually every 2-4 weeks, as suggested by the European Society of Cardiology 6
• Elderly patients may require lower doses of IV hydralazine due to increased sensitivity, and the American College of Cardiology recommends using IV hydralazine with caution in patients with advanced aortic stenosis 16
• Caution is recommended in patients with coronary ischemia as beta-blockers, including labetalol, may not effectively reduce coronary vasoconstriction, with a strength of evidence based on clinical trials 11